India, Oct. 14 -- Wednesday, MaxCyte, Inc. (MXCT), a cell-engineering company supporting the development of next-generation cell therapies, announced preliminary third-quarter revenue and raised its revenue guidance for 2026.
MaxCyte expects third-quarter core revenue of approximately $8.1 million, up 26% year-over-year. Strategic Platform License revenue is expected to exceed $1 million, including a $1 million milestone payment.
In addition, MaxCyte raised its 2026 revenue forecast to approximately $34 million, up from its previous guidance of $30 million-$32 million. This includes $28 million in core business revenue and $6 million from its Strategic Platform License program, comprising $4 million in milestone payments and $2 million in...